Elan, Wyeth suspend Alzheimer's vaccine study
NEW YORK, April 17
NEW YORK, April 17 (Reuters) - Elan Corp ELN.I said on Thursday that a mid-stage clinical trial of an Alzheimer's vaccine it is developing with Wyeth WYE.N has been suspended while the companies look into a potentially serious side effect suffered by one patient in the study.
Dosing in the study of the experimental vaccine, ACC-001, was halted after the patient was hospitalized with skin lesions from what the physician serving as lead researcher suspected was a case of vasculitis, an inflammation of blood vessels.
"Following discussion with the FDA, all further dosing has been suspended while this particular event is fully evaluated," Jonathan Birt, a spokesman for Ireland-based Elan, said.
The companies are in talks with health regulators and the physician to further understand the clinical and scientific issues, Birt added.
He said the patient has been released from the hospital and the lesions are healing.
The companies stressed that the vaccine and study in question has no connection to bapineuzumab, their lead Alzheimer's drug candidate also being developed with Wyeth that is in late-stage clinical testing. (Reporting by Bill Berkrot; Editing by Brian Moss)
- Malaysia military source says missing jet veered to west |
- Ukraine appeals to West as Crimea turns to Russia |
- Malaysia air probe finds scant evidence of attack: sources |
- UPDATE 1-Missing Malaysian plane last seen at Strait of Malacca-source
- CIA accused of spying on U.S. Senate intelligence committee